Cryoport : 2022 JPM Conference Presentation Slides

© 2021 Cryoport, Inc. All Rights Reserved

CYRX: NASDAQ

Cryoport - A Trusted Partner to Life Sciences Companies

Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions

Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as:

• CAR-Tand allogeneic therapies
• Human and animal reproductive materials
• Vaccines

Majority of cell therapies need to be shipped at cryogenic temperatures

A leading global manufacturer of cryogenic systems and supplies

One of the largest healthcare specialty logistics providers by revenue

Leading provider of temperature- controlled supply chain solutionsand

productsto the life sciences industry

Cryoport, Inc. (CYRX) operates as a operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry

© 2021 Cryoport, Inc. All Rights Reserved

2

A Global Leader of Temperature-Controlled Supply Chain

Solutions for the Life Sciences Industry

582

~44%

38%

$56.7MM

Active Cell & Gene Therapy

of all Phase III Regenerative

Organic Growth

Q3 2021 Revenue

Clinical Trials Supported (1)

Medicine Clinical Trials Supported (1,4)

in Revenue (2)

8	2000+	1MM+	36
Commercial Cell & Gene	Active Global Clients (1)	Shipments (3)	Clinical Trials - COVID-19 Vaccines /
Therapies Supported (1)			Treatments Supported (1)

Trusted Provider of Temperature-Controlled Supply Chain Solutions for Temperature-Sensitive Life Sciences Industry

Notes:

1. Data as of 9/30/21 2. Q3 2020-Q3 2021 Year over Year growth of Cryoport Systems and CRYOGENE 3. Total combined shipments of Cryoport Systems and CRYOPDP since inception 4. Derived from 70 Cryoport phase III trials divided by 158 Industry sponsored phase III trials.

© 2021 Cryoport, Inc. All Rights Reserved

3

Attractive High-Growth Regenerative Medicine Market

Driving Expected Demand

Therapies Approved by Modeling Scenario

# new therapies approved by FDA

150

				120
				2027
100				96
			79	2026
		72
56			2025
50				2024
				2023
				2022
				2021
0				2020
Lower trial success	Continued market	Faster rate	Faster rate + trial Higher approval rate
	rate	conditions	of approval	accel.

Patients Treated per Year in Trials of Commercially Approved Therapies

# of patients treated in-year with C> therapies (000's) in modeled scenarios

600	CAGR	CAGR
'20 - "24	'24 - "27
	43%	32%
	39%	30%
400	32%	32%
	27%	33%
	23%	30%
200

0
2020	2024	2027
	Lower trial success rate		Continued market conditions		Faster rate of approval
	Faster rate + trial accel.		Higher approval rate

Source: Leading third party consulting firm analysis

Notes: Some therapies, such as those focused on treating Hepatitis A and B, will drive higher patient populations; In order to avoid predicting success of individual therapies, we have assumed a standard number of treatable patients per therapy based on average incidents currently in trials. This rate assumes that the total patient population treatable by each therapy does not wholly "replenish" each year, given rare nature of many disease that C & GT targets

© 2021 Cryoport, Inc. All Rights Reserved

4

Dynamic and Expanding TAM

Cell & Gene Therapy Market Expected to Grow 40%+

Regenerative
Medicine	1,320	~1,195	$14.1 Bn	641
1H 2021	(1)
		Active Global	Gene, Cell & Tissue-Based	Total Global	Active Oncology
		Clinical Trials	therapeutic companies globally	Financing Raised	Clinical Trials

Cell & Gene Therapy Market (2)
$Bn			The acquisitions of CRYOPDP and MVE Biological Solutions expand
		Cryoport's addressable market and provide our customers with end-to-end support
40
	$33+	across the Cell and Gene Therapy value chain.
30				+
20
10	$4		Clinical Trial	Cryogenic
		Logistics	Systems
0
	2019	2024
		Source: (1) The Alliance for Regenerative Medicine (2)	Leading third party consulting analysis

© 2021 Cryoport, Inc. All Rights Reserved

5